Dynamic Healthcare M&A Database

Acquiring Party	Medicis Pharmaceutical Corporation (NYSE:MRX, a specialty pharmaceutical company focusing on the treatment of dermatological and aesthetic conditions.
Transferring Party	LipoSonix, Inc., a developer of non-invasive ultrasound technology to eliminate unwanted fat.
Sector	Medical Devices
Date	June 16, 2008
Analysis Broadens Medicis' aesthetics portfolio pipeline with an alternative to invasive liposuction for targeted fat reduction, addressing a large market of overweight people. LipoSonix recently launched its first product in Europe and Medicis anticipates entering the U.S. with the LipoSonix technology by 2011. A crew of venture investors will cash out via the sale: The Carlyle Group, Versant Ventures, Shroder Ventures Life Sciences, Accuitive Medical Ventures, Three Arch Partners, Delphi Ventures, Essex Woodlands Health Ventures and Pinnacle Ventures. Deal value ~ $150m, with up to an additional $150m upon FDA approval.
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason.

Dynamic Healthcare M&A Database - 2Q08